OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (63)	11/4/1999 11:13:00 PM
From: Miljenko Zuanic	Read Replies (1) of 447

Do not know, but I will guess that OSIP/PFE collaboration may only profit from AGPH/WLA R&D and clinical experience. However, some programs (overlapped ones) would probably be eliminated. This PFE (based on WLA/AHP action...$2 B in break-up fee) move looks to me like lousy loser attempt. I doubt that today neglected move in OSIP stock price is street reaction to PFE bid. They are not that sophisticated to connect things quickly. Hope that two PFE's cancer IND application are at FDA door/desk. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next